+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia



Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia



Open Access Macedonian Journal of Medical Sciences 5(7): 904-908



The primary objective of the study was to evaluate the overall survival of women with advanced stage (Stage IIIA-IV) high-grade serous ovarian cancer in Macedonia. The study was a cross-sectional medical record review of patients diagnosed with advanced stage HGSC. Patients were deemed eligible for inclusion if they were diagnosed with an advanced stage (Stage IIIA-IV) HGSC of the ovary, fallopian tube or peritoneum between 2009 and 2015. The data were analyzed in a descriptive fashion and summary statistics were provided, as appropriate. Survival was calculated using the Kaplan-Meier method. A total of 81 eligible patients were identified and included in the study. The average overall survival in the studied cohort was 46.59 months (95%CI = 39.11-54.06). Patients that were optimally debulked and patients that had a platinum-free interval larger than 12 months had significantly longer survival in the current series (p < 0.001). the average overall survival of advanced stage HGSC patients in the studied series was 46.59 months (95%CI = 39.11-54.06). Patients aged 65 years or younger tended to live approximately ten months longer than patients older than 65 years, but this difference was not statistically significant. There was no difference in HGSC survival in the groups of patients with grade 2 and grade 3 disease. However, optimal surgical debulking and platinum sensitivity were associated with significantly better overall survival.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 065549963

Download citation: RISBibTeXText

PMID: 29362616


Related references

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Journal of Ovarian Research 12(1): 40, 2019

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology 2019, 2019

Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstetrics and Gynecology 129(3): 439-447, 2017

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. Journal of Cancer Research and Clinical Oncology 2019, 2019

Identification of a gene signature that can predict lone-term survival in patients with high-grade late stage serous ovarian cancer. Journal of Clinical Oncology 23(16_Suppl): 5032-5032, 2016

Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma. International Journal of Gynecological Pathology 34(6): 497-506, 2016

Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research 19(4): 809-820, 2013

High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecologic Oncology 96(2): 355-361, 2005

Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer. Biological Chemistry 398(7): 765-773, 2016

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal 59(8): 930-936, 2018

Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer. Applied Immunohistochemistry and Molecular Morphology 25(2): 110-116, 2015

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). Bmc Cancer 19(1): 341, 2019

Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study. Journal of Gynecologic Oncology 29(1): E12, 2018

Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiology, Biomarkers and Prevention 2019, 2019

Human cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival. Medicine 97(4): E9685, 2018